Skip to main content

Table 2 Comparisons of clinical parameters between NASH patients seropositive and seronegative for ANAs

From: Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease

 

ANA-positive (n = 10)

ANA-positive (n = 15)

p value

Age (y.o.)

55.0 ± 6.3

52.9 ± 16.4

0.9115

Gender (male/female)

4/6

4/11

0.7794

BMI

28.3 ± 5.0

26.9 ± 4.3

0.6773

HOMA-IR value

6.81 ± 3.46 (n = 7)

4.00 ± 2.57 (n = 14)

0.0305

ALT (IU/L)

108 ± 82

135 ± 75

0.2018

IgG (mg/dL)

1833 ± 471

1292 ± 269

0.0055

Ferritin (ng/ml)

518 ± 270

229 ± 97

0.0041

Hepatic fibrosis (F0/F1/F2/F3/F4)

1/2/1/6/0

0/8/2/4/1

0.4055

Hepatic steatosis (grade 0/1/2)

3/2/5

6/5/4

0.3458

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us